Bicycle Therapeutics Reports Positive Zelenectide Pevedotin Data in Multiple Cancers

BICYCLE THERAPEUTICS PLC

Zelenectide pevedotin plus pembrolizumab showed 60% ORR in 22 first-line cisplatin-ineligible mUC patients.
Breast cancer patients with NECTIN4 gene amplification had 62.5% ORR (5/8) vs. 14.3% in all evaluable patients.
NSCLC patients with NECTIN4 gene amplification achieved 40.0% ORR (2/5); no responses in non-amplified patients.
Company plans Phase 1/2 trials in NECTIN4-amplified breast, lung, and other cancers in 2025.
Dose selection and topline data from Phase 2/3 Duravelo-2 trial expected in 2H 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.